Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

After several decades of development, the socialist market economy of China is now the world’s second largest economy by nominal GDP. China is also the largest economy by purchasing power parity according to the International Monetary Fund. In tandem with the development of the Chinese economy, China’s cancer burden is rising rapidly due to an ageing population and the adoption of unhealthy lifestyle behaviours. According to the data from the National Central Cancer Registry (NCCR) of China, the incidence and mortality of cancer have been increasing rapidly in China. In recent years, cancer has been the leading cause of death among city residents and the second cause of death among rural residents, which has become a stark public health issue in China. According to the NCCR, an estimated 4.29 million new incident cases (12 thousand per day) and 2.81 million death cases (7.5 thousand per day) would occur in 2015 in China. This corresponds to the age-standardized incidence rate (ASIR) of 201.1 per 100,000 and age-standardized mortality rate (ASMR) of 126.9 per 100,000, respectively. Due to the geographical and ethnical disparities in living habits and healthcare level, the cancer spectrum differs between different regions and ethnical groups in China. According to the estimation from IARC, the incidence of nasopharyngeal carcinoma and liver cancer is the world’s highest in specific regions of China. The incidence of some cancer types in Chinese urban areas, such as colorectal, prostate, kidney and bladder cancers, is similar to that in developed countries or regions where the incidence of cancer is highly associated with obesity and westernised lifestyles. Nevertheless, the incidence of some common cancer types in rural areas, including oesophageal, stomach, liver and cervical cancers, shares similarity with less developed countries or regions in the world where cancers are associated with chronic infectious agents due to poverty. In addition, the mortality rate is higher in rural areas, which suggests a poorer cancer prognosis due to late diagnosis and/or unsatisfying clinical treatment. The distinct cancer patterns of different regions and/or ethnic groups indicate a need for precise cancer prevention and control plans tailored for different geographical regions and/or ethnic groups. The overarching goal of the proposed Frontiers in Oncology Research Topic is to present current perspectives on cancer epidemiology in Chinese characteristics and provide current knowledge of cancer burden as well as cancer mortality to academic investigators, clinicians and stakeholders from the translational, clinical and public health communities.

Medicine --- Oncology --- cancer burden in China --- cancer mortality --- China --- public health --- cancer epidemiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

In 1998, health expenditures in the United States accounted for 12.9% of national income-the highest share of income devoted to health in the developed world. The United States also spends more on medical research than any other country-in 2000, the federal government dedicated

Medicine --- Research --- Cost effectiveness --- health expenditure, national income, medical research, government, funding, longevity, innovation, technology, development, fda, prescription drugs, pharmaceuticals, gdp, heart disease, cancer, mortality, cost effectiveness, economics, politics, economy, nonfiction, medicine, healthcare, living standards, biomedical, growth, quality of life, illness.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.

Medicine --- malondialdehyde --- oxidative stress --- new-onset diabetes --- renal transplantation --- BK virus --- BK virus nephropathy --- kidney allograft --- transplantation --- Alport syndrome --- children --- autosomal dominant polycystic kidney disease --- epidemiology --- hospitalization --- kidney transplantation --- subarachnoid hemorrhage --- malignancy --- post-transplant malignancy --- renal cell carcinoma --- meta-analysis --- systematic reviews --- tacrolimus --- C/D-ratio --- pharmacokinetics --- opportunistic infection --- allograft survival --- urological complications --- ureteric stent --- urinary tract infection --- timing of removal --- living donor --- ethnicity --- age --- obesity --- genetic relationship donor/recipient --- atypical hemolytic uremic syndrome --- eculizumab --- glucose intolerance --- insulin secretion --- insulin resistance --- oral glucose tolerance test --- healthy subject --- hyperchloremia --- kidney graft dysfunction --- living donor kidney transplantation --- Uropathogenic E. coli --- UPEC --- phylogeny --- genomics --- antibiotic resistance --- virulence traits --- night-time renal transplantation --- graft survival --- patient survival/outcome --- surgical complications --- acute rejection --- lymphocyte --- CD45RC --- Belatacept --- cardiovascular high risk --- outcome --- machine perfusion --- organ preservation --- temperature --- hypothermic --- normothermic --- transplant --- proton-pump inhibitors --- iron --- iron deficiency --- polyomavirus --- BKV --- kidney --- glomerulus --- BKVAN --- nephropathy --- fluid management --- delayed graft function --- goal-directed fluid therapy --- calcineurin inhibitor nephrotoxcity --- C/D ratio --- tacrolimus metabolism --- ADPKD --- native nephrectomy --- patient outcome --- perioperative complications --- epidermal growth factor --- creatinine --- graft failure --- renal transplantation. --- new onset diabetes after renal transplantation --- single nucleotide polymorphisms --- n/a --- urinary biomarkers --- α-GST --- π-GST --- nephrotoxicity --- urinary excretion of N1-methylnicotinamide --- mortality --- niacin status --- dietary intake --- tryptophan --- vitamin B3 --- Kidney transplant --- vitamin C --- cancer mortality --- oxidative stress. --- mycophenolic acid --- immunosuppression --- plasmapheresis --- oxalate --- hyperoxaluria --- kidney transplant recipients --- post-transplantation diabetes mellitus --- all-cause mortality --- cardiovascular mortality --- infectious mortality --- magnesium --- hypomagnesaemia --- cancer --- kidney transplant --- survival --- living kidney donation --- living-donor kidney transplantation --- beliefs --- inequity --- ischemia reperfusion injury --- innate immune system --- adaptive immune system --- apoptosis --- necrosis --- hypoxic inducible factor --- endothelial dysfunction --- proton pump inhibitor --- transplant rejection --- GFR --- insulin-like growth factor 1 --- growth hormone --- muscle mass --- patient survival --- physical activity --- renal transplant recipients --- kidney transplant (KT) --- donor-specific antibodies (DSA) --- C3d-binding assay --- antibody-mediated rejection (AMR) --- arsenic --- diet --- fish consumption --- post-transplant diabetes mellitus --- N1-methyl-2-pyridone-5-carboxamide --- N1-methylnicotinamide --- urinary excretion --- kidney function --- biomarker --- branched chain amino acids --- posttransplant diarrhea --- methanogenesis --- Methanosphaera stadtmanae --- mucins --- sulfate-reducing bacteria --- acute humoral rejection --- first-line therapy --- outcomes --- proteasome inhibitor --- renal transplant --- transplant recipients --- calcineurin inhibitors --- FK506 --- pharmacokinetic --- fast tacrolimus metabolizers

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.

malondialdehyde --- oxidative stress --- new-onset diabetes --- renal transplantation --- BK virus --- BK virus nephropathy --- kidney allograft --- transplantation --- Alport syndrome --- children --- autosomal dominant polycystic kidney disease --- epidemiology --- hospitalization --- kidney transplantation --- subarachnoid hemorrhage --- malignancy --- post-transplant malignancy --- renal cell carcinoma --- meta-analysis --- systematic reviews --- tacrolimus --- C/D-ratio --- pharmacokinetics --- opportunistic infection --- allograft survival --- urological complications --- ureteric stent --- urinary tract infection --- timing of removal --- living donor --- ethnicity --- age --- obesity --- genetic relationship donor/recipient --- atypical hemolytic uremic syndrome --- eculizumab --- glucose intolerance --- insulin secretion --- insulin resistance --- oral glucose tolerance test --- healthy subject --- hyperchloremia --- kidney graft dysfunction --- living donor kidney transplantation --- Uropathogenic E. coli --- UPEC --- phylogeny --- genomics --- antibiotic resistance --- virulence traits --- night-time renal transplantation --- graft survival --- patient survival/outcome --- surgical complications --- acute rejection --- lymphocyte --- CD45RC --- Belatacept --- cardiovascular high risk --- outcome --- machine perfusion --- organ preservation --- temperature --- hypothermic --- normothermic --- transplant --- proton-pump inhibitors --- iron --- iron deficiency --- polyomavirus --- BKV --- kidney --- glomerulus --- BKVAN --- nephropathy --- fluid management --- delayed graft function --- goal-directed fluid therapy --- calcineurin inhibitor nephrotoxcity --- C/D ratio --- tacrolimus metabolism --- ADPKD --- native nephrectomy --- patient outcome --- perioperative complications --- epidermal growth factor --- creatinine --- graft failure --- renal transplantation. --- new onset diabetes after renal transplantation --- single nucleotide polymorphisms --- n/a --- urinary biomarkers --- α-GST --- π-GST --- nephrotoxicity --- urinary excretion of N1-methylnicotinamide --- mortality --- niacin status --- dietary intake --- tryptophan --- vitamin B3 --- Kidney transplant --- vitamin C --- cancer mortality --- oxidative stress. --- mycophenolic acid --- immunosuppression --- plasmapheresis --- oxalate --- hyperoxaluria --- kidney transplant recipients --- post-transplantation diabetes mellitus --- all-cause mortality --- cardiovascular mortality --- infectious mortality --- magnesium --- hypomagnesaemia --- cancer --- kidney transplant --- survival --- living kidney donation --- living-donor kidney transplantation --- beliefs --- inequity --- ischemia reperfusion injury --- innate immune system --- adaptive immune system --- apoptosis --- necrosis --- hypoxic inducible factor --- endothelial dysfunction --- proton pump inhibitor --- transplant rejection --- GFR --- insulin-like growth factor 1 --- growth hormone --- muscle mass --- patient survival --- physical activity --- renal transplant recipients --- kidney transplant (KT) --- donor-specific antibodies (DSA) --- C3d-binding assay --- antibody-mediated rejection (AMR) --- arsenic --- diet --- fish consumption --- post-transplant diabetes mellitus --- N1-methyl-2-pyridone-5-carboxamide --- N1-methylnicotinamide --- urinary excretion --- kidney function --- biomarker --- branched chain amino acids --- posttransplant diarrhea --- methanogenesis --- Methanosphaera stadtmanae --- mucins --- sulfate-reducing bacteria --- acute humoral rejection --- first-line therapy --- outcomes --- proteasome inhibitor --- renal transplant --- transplant recipients --- calcineurin inhibitors --- FK506 --- pharmacokinetic --- fast tacrolimus metabolizers

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.

Medicine --- malondialdehyde --- oxidative stress --- new-onset diabetes --- renal transplantation --- BK virus --- BK virus nephropathy --- kidney allograft --- transplantation --- Alport syndrome --- children --- autosomal dominant polycystic kidney disease --- epidemiology --- hospitalization --- kidney transplantation --- subarachnoid hemorrhage --- malignancy --- post-transplant malignancy --- renal cell carcinoma --- meta-analysis --- systematic reviews --- tacrolimus --- C/D-ratio --- pharmacokinetics --- opportunistic infection --- allograft survival --- urological complications --- ureteric stent --- urinary tract infection --- timing of removal --- living donor --- ethnicity --- age --- obesity --- genetic relationship donor/recipient --- atypical hemolytic uremic syndrome --- eculizumab --- glucose intolerance --- insulin secretion --- insulin resistance --- oral glucose tolerance test --- healthy subject --- hyperchloremia --- kidney graft dysfunction --- living donor kidney transplantation --- Uropathogenic E. coli --- UPEC --- phylogeny --- genomics --- antibiotic resistance --- virulence traits --- night-time renal transplantation --- graft survival --- patient survival/outcome --- surgical complications --- acute rejection --- lymphocyte --- CD45RC --- Belatacept --- cardiovascular high risk --- outcome --- machine perfusion --- organ preservation --- temperature --- hypothermic --- normothermic --- transplant --- proton-pump inhibitors --- iron --- iron deficiency --- polyomavirus --- BKV --- kidney --- glomerulus --- BKVAN --- nephropathy --- fluid management --- delayed graft function --- goal-directed fluid therapy --- calcineurin inhibitor nephrotoxcity --- C/D ratio --- tacrolimus metabolism --- ADPKD --- native nephrectomy --- patient outcome --- perioperative complications --- epidermal growth factor --- creatinine --- graft failure --- renal transplantation. --- new onset diabetes after renal transplantation --- single nucleotide polymorphisms --- urinary biomarkers --- α-GST --- π-GST --- nephrotoxicity --- urinary excretion of N1-methylnicotinamide --- mortality --- niacin status --- dietary intake --- tryptophan --- vitamin B3 --- Kidney transplant --- vitamin C --- cancer mortality --- oxidative stress. --- mycophenolic acid --- immunosuppression --- plasmapheresis --- oxalate --- hyperoxaluria --- kidney transplant recipients --- post-transplantation diabetes mellitus --- all-cause mortality --- cardiovascular mortality --- infectious mortality --- magnesium --- hypomagnesaemia --- cancer --- kidney transplant --- survival --- living kidney donation --- living-donor kidney transplantation --- beliefs --- inequity --- ischemia reperfusion injury --- innate immune system --- adaptive immune system --- apoptosis --- necrosis --- hypoxic inducible factor --- endothelial dysfunction --- proton pump inhibitor --- transplant rejection --- GFR --- insulin-like growth factor 1 --- growth hormone --- muscle mass --- patient survival --- physical activity --- renal transplant recipients --- kidney transplant (KT) --- donor-specific antibodies (DSA) --- C3d-binding assay --- antibody-mediated rejection (AMR) --- arsenic --- diet --- fish consumption --- post-transplant diabetes mellitus --- N1-methyl-2-pyridone-5-carboxamide --- N1-methylnicotinamide --- urinary excretion --- kidney function --- biomarker --- branched chain amino acids --- posttransplant diarrhea --- methanogenesis --- Methanosphaera stadtmanae --- mucins --- sulfate-reducing bacteria --- acute humoral rejection --- first-line therapy --- outcomes --- proteasome inhibitor --- renal transplant --- transplant recipients --- calcineurin inhibitors --- FK506 --- pharmacokinetic --- fast tacrolimus metabolizers --- malondialdehyde --- oxidative stress --- new-onset diabetes --- renal transplantation --- BK virus --- BK virus nephropathy --- kidney allograft --- transplantation --- Alport syndrome --- children --- autosomal dominant polycystic kidney disease --- epidemiology --- hospitalization --- kidney transplantation --- subarachnoid hemorrhage --- malignancy --- post-transplant malignancy --- renal cell carcinoma --- meta-analysis --- systematic reviews --- tacrolimus --- C/D-ratio --- pharmacokinetics --- opportunistic infection --- allograft survival --- urological complications --- ureteric stent --- urinary tract infection --- timing of removal --- living donor --- ethnicity --- age --- obesity --- genetic relationship donor/recipient --- atypical hemolytic uremic syndrome --- eculizumab --- glucose intolerance --- insulin secretion --- insulin resistance --- oral glucose tolerance test --- healthy subject --- hyperchloremia --- kidney graft dysfunction --- living donor kidney transplantation --- Uropathogenic E. coli --- UPEC --- phylogeny --- genomics --- antibiotic resistance --- virulence traits --- night-time renal transplantation --- graft survival --- patient survival/outcome --- surgical complications --- acute rejection --- lymphocyte --- CD45RC --- Belatacept --- cardiovascular high risk --- outcome --- machine perfusion --- organ preservation --- temperature --- hypothermic --- normothermic --- transplant --- proton-pump inhibitors --- iron --- iron deficiency --- polyomavirus --- BKV --- kidney --- glomerulus --- BKVAN --- nephropathy --- fluid management --- delayed graft function --- goal-directed fluid therapy --- calcineurin inhibitor nephrotoxcity --- C/D ratio --- tacrolimus metabolism --- ADPKD --- native nephrectomy --- patient outcome --- perioperative complications --- epidermal growth factor --- creatinine --- graft failure --- renal transplantation. --- new onset diabetes after renal transplantation --- single nucleotide polymorphisms --- urinary biomarkers --- α-GST --- π-GST --- nephrotoxicity --- urinary excretion of N1-methylnicotinamide --- mortality --- niacin status --- dietary intake --- tryptophan --- vitamin B3 --- Kidney transplant --- vitamin C --- cancer mortality --- oxidative stress. --- mycophenolic acid --- immunosuppression --- plasmapheresis --- oxalate --- hyperoxaluria --- kidney transplant recipients --- post-transplantation diabetes mellitus --- all-cause mortality --- cardiovascular mortality --- infectious mortality --- magnesium --- hypomagnesaemia --- cancer --- kidney transplant --- survival --- living kidney donation --- living-donor kidney transplantation --- beliefs --- inequity --- ischemia reperfusion injury --- innate immune system --- adaptive immune system --- apoptosis --- necrosis --- hypoxic inducible factor --- endothelial dysfunction --- proton pump inhibitor --- transplant rejection --- GFR --- insulin-like growth factor 1 --- growth hormone --- muscle mass --- patient survival --- physical activity --- renal transplant recipients --- kidney transplant (KT) --- donor-specific antibodies (DSA) --- C3d-binding assay --- antibody-mediated rejection (AMR) --- arsenic --- diet --- fish consumption --- post-transplant diabetes mellitus --- N1-methyl-2-pyridone-5-carboxamide --- N1-methylnicotinamide --- urinary excretion --- kidney function --- biomarker --- branched chain amino acids --- posttransplant diarrhea --- methanogenesis --- Methanosphaera stadtmanae --- mucins --- sulfate-reducing bacteria --- acute humoral rejection --- first-line therapy --- outcomes --- proteasome inhibitor --- renal transplant --- transplant recipients --- calcineurin inhibitors --- FK506 --- pharmacokinetic --- fast tacrolimus metabolizers